Photo of Al Charest,  PhD

Al Charest, PhD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-5687


acharest@bidmc.harvard.edu

Photo of Al Charest,  PhD

Beth Israel Deaconess Medical Center
Phone: (617) 667-5687


acharest@bidmc.harvard.edu

Member Summary Video
Visualize Collaborations

Al Charest, PhD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Associate Professor, Medicine, Beth Israel Deaconess Medical Center
  • Member, Cancer Research Institute, Beth Israel Deaconess Medical Center

HCC PROGRAM AFFILIATION

Research Abstract

Reconstituting Human Cancer Gene Mutations in Mice Through Genetic Engineering to Accurately Model Cancer

A major drive of the lab is to model primary brain cancer (low and high grade gliomas) in genetically engineered mouse models to study the molecular and microenvironmental processes driving the initiation and maintenance of these cancers.

We are particularly interested in elucidating the elements that dictate how a normal cell responds to specific oncogenic mutations at the molecular level and how the resulting cancer cell wiring can be exploited for therapeutic intervention.

Identifying Novel Cancer Targets, Eploiting Signaling Vulnerabilities and Developping Pre- and Co-Clinical Trial Programs

Using orthogonal approaches, we strive to decipher the complexities of signal transduction pathways in cancer and to reveal molecular vulnerabilities.

Integrating Glioma Cancer Mutations With Tumor Immunology

We are determining the immunological landscape of high grade glioma (Glioblastoma Multiforme) in genetically-defined mouse models and from clinical sources.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Kumar S, Sinclair JA, Shi T, Kim G, Zhu R, Gasper G, Wang Y, Higginbotham JN, Zhang Q, Jeppesen DK, Tutanov O, Hamilton M, Franklin JL, Charest A, Coffey RJ, Senapati S, Chang HC. Surface markers on supermeres outperform extracellular vesicles in colorectal cancer diagnosis. Sci Rep 2026. PubMed
  • Xu T, Paulo JA, Zhang P, Liu X, Nguyen A, Cheng Y, Massick C, Zhang Y, Jeppesen DK, Zhang Q, Higginbotham JN, Tutanov OS, Krichevsky AM, Chiu DT, Gygi SP, Vickers KC, Franklin JL, Coffey RJ, Charest A. Heterogeneity of Extracellular Vesicles and Non-Vesicular Nanoparticles in Glioblastoma. J Extracell Vesicles 2025; 14:e70168. PubMed
  • Abou Haidar E, Prabhakar S, Cheah PS, Hanlon KS, Espinoza P, Crain AV, Patel N, Radcliff GW, Cheng M, Hernández IC, Minderler S, de la Cruz D, Ng C, da Hora CC, Charest A, Stemmer-Rachamimov A, Jowett N, Breakefield XO, Maguire CA. Engineered AAV capsids mediate transduction of murine neurofibroma and sciatic nerve. Gene Ther 2025. PubMed
  • Jun HJ, Paulo JA, Appleman VA, Yaron-Barir TM, Johnson JL, Yeo AT, Rogers VA, Kuang S, Varma H, Gygi SP, Trotman LC, Charest A. Pleiotropic tumor suppressive functions of PTEN missense mutations during gliomagenesis. iScience 2024; 27:111278. PubMed
  • Kim J, Xu S, Jung SR, Nguyen A, Cheng Y, Zhao M, Fujimoto BS, Nelson W, Schiro P, Franklin JL, Higginbotham JN, Coffey RJ, Shi M, Vojtech LN, Hladik F, Tewari M, Tigges J, Ghiran I, Jovanovic-Talisman T, Laurent LC, Das S, Gololobova O, Witwer KW, Xu T, Charest A, Jensen KVK, Raffai RL, Jones JC, Welsh JA, Nolan JP, Chiu DT. Comparison of EV characterization by commercial high-sensitivity flow cytometers and a custom single-molecule flow cytometer. J Extracell Vesicles 2024; 13:e12498. PubMed
  • Morey A, Ng M, Spanos M, Zhang P, Xu T, Cheung W, Chatterjee E, Gokulnath P, Carnel-Amar N, Soares Chiaretti AL, Nelson C, George J, Luo M, Chakraborty A, Perucci L, Jones JC, Hoff P, Franklin JL, Raffai RL, Das S, Routenberg DA, Nolan JP, Charest A, Laurent LC, Alexander RP. The EV antibody database: An interactive database of curated antibodies for extracellular vesicle and nanoparticle research. Extracell Vesicle 2024. PubMed
  • Yeo AT, Shah R, Aliazis K, Pal R, Xu T, Zhang P, Rawal S, Rose CM, Varn FS, Appleman VA, Yoon J, Varma H, Gygi SP, Verhaak RGW, Boussiotis VA, Charest A. Driver mutations dictate the immunological landscape and response to checkpoint immunotherapy of glioblastoma. Cancer Immunol Res 2023. PubMed
  • Mateescu B, Jones JC, Alexander RP, Alsop E, An JY, Asghari M, Boomgarden A, Bouchareychas L, Cayota A, Chang HC, Charest A, Chiu DT, Coffey RJ, Das S, De Hoff P, deMello A, D'Souza-Schorey C, Elashoff D, Eliato KR, Franklin JL, Galas DJ, Gerstein MB, Ghiran IH, Go DB, Gould S, Grogan TR, Higginbotham JN, Hladik F, Huang TJ, Huo X, Hutchins E, Jeppesen DK, Jovanovic-Talisman T, Kim BYS, Kim S, Kim KM, Kim Y, Kitchen RR, Knouse V, LaPlante EL, Lebrilla CB, Lee LJ, Lennon KM, Li G, Li F, Li T, Liu T, Liu Z, Maddox AL, McCarthy K, Meechoovet B, Maniya N, Meng Y, Milosavljevic A, Min BH, Morey A, Ng M, Nolan J, De Oliveira Junior GP, Paulaitis ME, Phu TA, Raffai RL, Reátegui E, Roth ME, Routenberg DA, Rozowsky J, Rufo J, Senapati S, Shachar S, Sharma H, Sood AK, Stavrakis S, Stürchler A, Tewari M, Tosar JP, Tucker-Schwartz AK, Turchinovich A, Valkov N, Van Keuren-Jensen K, Vickers KC, Vojtech L, Vreeland WN, Wang C, Wang K, Wang Z, Welsh JA, Witwer KW, Wong DTW, Xia J, Xie YH, Yang K, Zaborowski MP, Zhang C, Zhang Q, Zivkovic AM, Laurent LC. Phase 2 of extracellular RNA communication consortium charts next-generation approaches for extracellular RNA research. iScience 2022; 25:104653. PubMed
  • Yeo AT, Rawal S, Delcuze B, Christofides A, Atayde A, Strauss L, Balaj L, Rogers VA, Uhlmann EJ, Varma H, Carter BS, Boussiotis VA, Charest A. Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression. Nat Immunol 2022; 23:971-984. PubMed
  • Yeo AT, Jun HJ, Appleman VA, Zhang P, Varma H, Sarkaria JN, Charest A. EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma. Oncogene 2021; 40:2682-2696. PubMed
  • Zeng A, Wei Z, Rabinovsky R, Jun HJ, El Fatimy R, Deforzh E, Arora R, Yao Y, Yao S, Yan W, Uhlmann EJ, Charest A, You Y, Krichevsky AM. Glioblastoma-Derived Extracellular Vesicles Facilitate Transformation of Astrocytes via Reprogramming Oncogenic Metabolism. iScience 2020; 23:101420. PubMed
  • Charest A. Experimental and Biological Insights from Proteomic Analyses of Extracellular Vesicle Cargos in Normalcy and Disease. Adv Biosyst 2020. PubMed
  • Ko J, Wang Y, Carlson JCT, Marquard A, Gungabeesoon J, Charest A, Weitz D, Pittet MJ, Weissleder R. Single Extracellular Vesicle Protein Analysis Using Immuno-Droplet Digital Polymerase Chain Reaction Amplification. Adv Biosyst 2020; 4:e1900307. PubMed
  • Vidal B, Bryke C, Hsu N, Alterman R, Yeo AT, Charest A, Varma H. A high-grade glioma with amplification. Clin Neuropathol 2019. PubMed
  • Gyuris A, Navarrete-Perea J, Jo A, Cristea S, Zhou S, Fraser K, Wei Z, Krichevsky AM, Weissleder R, Lee H, Gygi SP, Charest A. Physical and Molecular Landscapes of Mouse Glioma Extracellular Vesicles Define Heterogeneity. Cell Rep 2019; 27:3972-3987.e6. PubMed
  • Jun HJ, Appleman VA, Wu HJ, Rose CM, Pineda JJ, Yeo AT, Delcuze B, Lee C, Gyuris A, Zhu H, Woolfenden S, Bronisz A, Nakano I, Chiocca EA, Bronson RT, Ligon KL, Sarkaria JN, Gygi SP, Michor F, Mitchison TJ, Charest A. A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. Nat Commun 2018; 9:3116. PubMed
  • Zhou S, Appleman VA, Rose CM, Jun HJ, Yang J, Zhou Y, Bronson RT, Gygi SP, Charest A. Chronic platelet-derived growth factor receptor signaling exerts control over initiation of protein translation in glioma. Life Sci Alliance 2018; 1:e201800029. PubMed
  • Boussiotis VA, Charest A. Immunotherapies for malignant glioma. Oncogene 2017. PubMed
  • Yeo AT, Charest A. Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma. J Cell Biochem 2017; 118:2516-2527. PubMed
Hide
Member Summary Video